What is the 13F Pro Quality Score for MRK?

13F Pro ranks Merck & Co., Inc. (MRK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MRK's current score at https://13fpro.ai/company/MRK (free sign-up required for the full ranking).

Which hedge funds own the most MRK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MRK include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MRK as soon as new 13F filings post.

Where does 13F Pro source MRK data?

All Merck & Co., Inc. fundamentals and ownership data come directly from SEC EDGAR. Merck & Co., Inc. files with the SEC under CIK 310158. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MRK in?

Merck & Co., Inc. (MRK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives MRK's revenue?

Per Merck & Co., Inc.'s latest 10-Q filed with the SEC on 2026-08-07, the biggest revenue drivers are: Pharmaceutical ($14,760M); Keytruda/Keytruda Qlex ($8,366M, +5% YoY); Animal Health ($1,775M, +8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/MRK.

What are MRK's largest expenses?

Merck & Co., Inc.'s latest 10-Q reports these as the largest expense items: Research and development ($9,741M); Cost of sales ($4,395M, +24% YoY); Selling, general and administrative ($2,904M, +10% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is MRK research updated on 13F Pro?

MRK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Merck & Co., Inc.(MRK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmega

Institutional-grade research for retail investors

SEC EDGAR: CIK 310158 MRK stock profile & AI dashboard →

13F Pro Quality Score

59.9/100

Rank #897 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

33.8/100

Profitability

34.3/100

Balance Sheet

56.7/100

Earnings Quality

97.4/100

Free Cash Flow

77.8/100

Institutional Flow

65.5/100

Revenue Scale

97.7/100

Dilution Risk

50.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MRK Scores 60/100

exact factor attribution · 2026-09-11

MRK's composite is driven by scale and earnings quality, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+7.2 pts

98th pct

Earnings quality

+4.7 pts

97th pct

Free cash flow

+4.2 pts

78th pct

Institutional flow

+0.8 pts

66th pct

Capital efficiency

+0.7 pts

57th pct

Shareholder dilution

+0.0 pts

51th pct

Earnings growth

-2.0 pts

10th pct

Profitability

-2.4 pts

34th pct

Revenue growth

-3.2 pts

34th pct

Latest change (2026-08-07): 71 → 55 · ↓ Profit margin 72→38; ↓ Capital efficiency 82→54

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in MRK

Events flagged as statistical outliers against MRK's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-07
MRK quality score dropped 16 points (71→55) on a new filing
View source filing →

MRK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Merck & Co., Inc. (MRK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRK at 59.9/100 on a 32-signal composite quality model, placing it at rank #897 of 2,961 stocks — the top half of the AI-ranked universe. MRK scores in the top quartile across revenue scale (97.7), earnings quality (97.4), free cash flow (77.8). Areas of concern include revenue growth (33.8) and profitability (34.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Merck & Co., Inc. reports quarterly revenue of $16.6B, net income of $-1.3B, free cash flow of $4.5B. Top institutional holders of MRK by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. MRK trades on the NYSE exchange and files with the SEC under CIK 310158. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Merck & Co., Inc. directly from SEC EDGAR. Merck & Co., Inc.'s 13F Pro composite quality score has ranged between 55 and 82 since 2021, currently 59.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Merck & Co., Inc.

Quirks, history, and lore behind MRK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mega-cap · listed on the NYSE · headquartered in New Jersey.
2
The Numbers
Annual revenue around $60 billion, with an R&D budget that rivals the GDP of a small nation — over $13 billion a year spent hunting for the next blockbuster drug.
3
The History
Traces its American roots to 1891, when a German chemist set up a chemical shop in New York; its parent company was actually seized as enemy property during World War I.
4
The Secret
It spun off its consumer health brands into a separate company in 2021, doubling down on prescription drugs and vaccines as its entire reason for being.
5
The Lore
Its antiviral pill Lagevrio and its cancer immunotherapy rival made it a household name during two of the biggest medical crises in recent memory — one viral, one oncological.
6
The Giveaway
The maker of Keytruda — the world's best-selling cancer drug — and the HPV vaccine Gardasil, this pharma giant shares a name with a German company it hasn't been related to in over a century.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving MRK's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from Merck & Co., Inc.'s 10-Q filed 2026-08-07 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Sales rose 5% to $16.6B, but a $5.7B IPR&D charge for the Terns acquisition drove R&D to $9.7B and a $1,335M net loss.

Biggest Revenue Drivers

Pharmaceutical$14,760M

Growth in oncology and cardiometabolic and respiratory, partially offset by declines in diabetes and infectious diseases.

Animal Health$1,775M+8% YoY

Livestock up 8% on ruminant and poultry demand; companion animal up 7% on new product launches.

Biggest Revenue Drivers

Total revenue: $16.6B+5% YoY

Pharmaceutical$14,760M

Growth in oncology and cardiometabolic and respiratory, partially offset by declines in diabetes and infectious diseases.

Within Pharmaceutical

Keytruda/Keytruda Qlex$8,366M+5% YoY

U.S. higher net pricing and increased demand across earlier-stage indications; international demand in urothelial and endometrial cancer.

Winrevair$588M+75% YoY

Continued uptake in the U.S. and early launch uptake in certain international markets, particularly Japan and Europe.

Januvia/Janumet$429M-31% YoY

Lower U.S. sales from competitive pressure and lower net pricing; lower demand in China and generic competition internationally.

Animal Health$1,775M+8% YoY

Livestock up 8% on ruminant and poultry demand; companion animal up 7% on new product launches.

Largest Expense Items

Research and development$9,741M

Higher charges for business development, including $5.7B for Terns; partly offset by $200M Blackstone funding reduction.

Cost of sales$4,395M+24% YoY

Higher intangible amortization of $984M, Verona Pharma inventory step-up of $83M, and $184M of restructuring expenses.

Selling, general and administrative$2,904M+10% YoY

Higher administrative costs including IT investments, higher promotional and selling costs supporting launches, and unfavorable foreign exchange.

Restructuring costs$151M-73% YoY

Separation and other costs under the 2024 and 2025 restructuring programs.

Margins: Gross margin fell to 73.5% from 77.5%, primarily on higher intangible amortization, higher inventory write-downs (mainly vaccines), increased restructuring costs, and Verona Pharma inventory step-up, partly offset by favorable product mix.

Watch Items from the Filing

Keytruda/Keytruda Qlex is $8,366M of $16,607M total sales; Merck expects Keytruda to be selected for government price setting effective January 1, 2029.
Januvia and Janumet lost U.S. exclusivity May 2026, Janumet XR July 2026, and Bridion ($497M, +8%) lost U.S. exclusivity July 2026.
IRS Notices of Proposed Adjustment would raise the transition tax by roughly $1.3 billion plus about $260 million of penalties, excluding interest.
German court awarded Halozyme a preliminary injunction prohibiting subcutaneous pembrolizumab sales in Germany; appeal hearing set for November 19, 2026.
China sales fell to $408M from $446M; Gardasil shipments to China only resumed on a limited basis with immaterial 2026 revenue expected.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$16.6B

Net Income

Q2 2026

$-1.3B

Free Cash Flow

Q2 2026

$4.5B

ROIC

Q2 2026

-2.9%

D/E Ratio

Q2 2026

1.29

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1.3% YoY

$65.01BFY 2025

FY22 $59.28BFY23 $60.12BFY24 $64.17BFY25 $65.01B

Net Income

+6.6% YoY

$18.25BFY 2025

FY22 $14.52BFY23 $365.0MFY24 $17.12BFY25 $18.25B

EPS (Diluted)

+8.0% YoY

$7.28FY 2025

FY22 $5.71FY23 $0.14FY24 $6.74FY25 $7.28

Total Assets

+16.9% YoY

$136.87BFY 2025

FY22 $109.16BFY23 $106.67BFY24 $117.11BFY25 $136.87B

Total Debt

+32.9% YoY

$49.30BFY 2025

FY22 $30.70BFY23 $35.10BFY24 $37.10BFY25 $49.30B

Op. Cash Flow

-23.3% YoY

$16.47BFY 2025

FY22 $19.09BFY23 $13.01BFY24 $21.47BFY25 $16.47B

Free Cash Flow

-31.7% YoY

$12.36BFY 2025

FY22 $14.71BFY23 $9.14BFY24 $18.10BFY25 $12.36B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$65.01B +1.3%	$64.17B +6.7%	$60.12B +1.4%	$59.28B +21.7%	$48.70B +17.3%	$41.52B
Net Income	$18.25B +6.6%	$17.12B +4589.6%	$365.0M -97.5%	$14.52B +11.3%	$13.05B +84.6%	$7.07B
EPS (Diluted)	$7.28 +8.0%	$6.74 +4714.3%	$0.14 -97.5%	$5.71 +11.1%	$5.14 +84.9%	$2.78
Total Assets	$136.87B +16.9%	$117.11B +9.8%	$106.67B -2.3%	$109.16B +3.3%	$105.69B +15.4%	$91.59B
Total Debt	$49.30B +32.9%	$37.10B +5.7%	$35.10B +14.3%	$30.70B -7.3%	$33.10B +4.1%	$31.80B
Operating Cash Flow	$16.47B -23.3%	$21.47B +65.1%	$13.01B -31.9%	$19.09B	—	$10.25B
Free Cash Flow	$12.36B -31.7%	$18.10B +97.9%	$9.14B -37.8%	$14.71B	—	$5.82B

Get alerted when MRK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Merck & Co., Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MRK

BlackRock, Inc.
$29.2B226,999,837 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.7B161,323,174 sh
STATE STREET CORP
$15.6B120,413,256 sh
WELLINGTON MANAGEMENT GROUP LLP
$11.1B86,249,283 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$8.7B67,738,969 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.8B60,744,214 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$7.0B54,365,289 sh
MORGAN STANLEY
$6.3B48,641,158 sh
FMR LLC
$5.8B45,440,355 sh
JPMORGAN CHASE & CO
$5.7B43,886,420 sh

Fund	Value	Shares
BlackRock, Inc.	$29.2B	226,999,837
VANGUARD CAPITAL MANAGEMENT LLC	$20.7B	161,323,174
STATE STREET CORP	$15.6B	120,413,256
WELLINGTON MANAGEMENT GROUP LLP	$11.1B	86,249,283
VANGUARD PORTFOLIO MANAGEMENT LLC	$8.7B	67,738,969
GEODE CAPITAL MANAGEMENT, LLC	$7.8B	60,744,214
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$7.0B	54,365,289
MORGAN STANLEY	$6.3B	48,641,158
FMR LLC	$5.8B	45,440,355
JPMORGAN CHASE & CO	$5.7B	43,886,420

Companies Similar to MRK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

JNJ

JOHNSON & JOHNSON

AI score

Highly similar · 52 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Grantham, Mayo, Van Otterloo & Co. LLC Swedbank AB

ABBV

AbbVie Inc.

AI score

Highly similar · 50 shared holders

Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

PFE

PFIZER INC

AI score

Highly similar · 41 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO PeakShares LLC LSV ASSET MANAGEMENT

ABT

ABBOTT LABORATORIES

AI score

Very similar · 45 shared holders

Capital International Investors STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Grantham, Mayo, Van Otterloo & Co. LLC

UNH

UNITEDHEALTH GROUP INC

AI score

Very similar · 49 shared holders

Capital International Investors Grantham, Mayo, Van Otterloo & Co. LLC National Pension Service

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 45 shared holders

LSV ASSET MANAGEMENT NORDEA INVESTMENT MANAGEMENT AB Capital International Investors

GILD

GILEAD SCIENCES, INC.

AI score

Very similar · 51 shared holders

PeakShares LLC NORDEA INVESTMENT MANAGEMENT AB National Pension Service

AMGN

AMGEN INC

AI score

Very similar · 51 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Aristotle Capital Management, LLC Capital Wealth Planning, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MRK on your watchlist

Track score changes the day Merck & Co., Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MRK a good stock to buy?

13F Pro's AI-powered analysis of Merck & Co., Inc. (MRK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRK are available on the MRK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MRK is classified as a mega company.

Which hedge funds own MRK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Merck & Co., Inc.'s investment landscape.